Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: a retrospective analysis

被引：0
|
作者：
T. Korkmaz
S. Seber
U. Kefeli
E. Sari
M. Canhoroz
B. Oven
E. Yildirim
N. Yasar
D. Aydin
O. Balvan
N. Sener
S. Yuksel
A. Mert
O. Polat
F. Yumuk
O. Kanat
M. Gumus
N. S. Turhal
机构：
[1] Dr. Lutfi Kirdar Kartal Education and Research Hospital,Department of Medical Oncology
[2] Marmara University Hospital,Medical Oncology Department
[3] Uludag University Hospital,Medical Oncology Department
[4] Marmara University Hospital,Internal Medicine Department
来源：
Clinical and Translational Oncology | 2013年 / 15卷
关键词：
Platinum sensitive disease; Platinum refracter disease; Second-line chemotherapy; Small cell lung cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：535 / 540
页数：5
相关论文
共 50 条
  • [21] Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease
    Ardizzoni, A
    Hansen, H
    Dombernowsky, P
    Gamucci, T
    Kaplan, S
    Postmus, P
    Giaccone, G
    Schaefer, B
    Wanders, J
    Verweij, J
    JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (05) : 2090 - 2096
  • [22] Combination chemotherapy with irinotecan and ifosfamide as second-line treatment of refractory or sensitive relapsed small cell lung cancer: A phase II study
    Ichiki, M
    Gohara, R
    Rikimaru, T
    Kitajima, T
    Fujiki, R
    Shimada, A
    Aizawa, H
    CHEMOTHERAPY, 2003, 49 (04) : 200 - 205
  • [23] Validation of standard definition of sensitive versus refractory relapsed small cell lung cancer: A pooled analysis of topotecan second-line trials
    Ardizzoni, Andrea
    Tiseo, Marcello
    Boni, Luca
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (13) : 2211 - 2218
  • [24] Sacituzumab Govitecan as Second-Line Treatment in Patients with Extensive Stage Small Cell Lung Cancer
    Dowlati, A.
    Chiang, A. C.
    Cervantes, A.
    Babu, S.
    Hamilton, E.
    Wong, S. F.
    Tazbirkova, A.
    Sullivan, I. G.
    van Marcke, C.
    Italiano, A.
    Patel, J.
    Mekan, S.
    Wu, T.
    Waqar, S. N.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S16 - S16
  • [25] OUR EXPERIENCE WITH TOPOTECAN AS SECOND-LINE TREATMENT OF PATIENTS WITH RELAPSED SMALL CELL LUNG CANCER
    Davidov, Deyan
    JOURNAL OF IMAB, 2010, 16 (03): : 70 - 73
  • [26] NGR-hTNF and Doxorubicin as Second-Line Treatment of Patients with Small Cell Lung Cancer
    Gregorc, Vanesa
    Cavina, Raffaele
    Novello, Sivia
    Grossi, Francesco
    Lazzari, Chiara
    Capelletto, Enrica
    Genova, Carlo
    Salini, Giulia
    Lambiase, Antonio
    Santoro, Armando
    ONCOLOGIST, 2018, 23 (10): : 1133 - +
  • [27] Meta-Analysis of Second Line Chemotherapy Efficacy in Sensitive and Refractory Small Cell Lung Cancer (SCLC) Patients
    Owonikoko, T. K.
    Behera, M.
    Chen, Z.
    Bhimani, C.
    Curran, W. J.
    Khuri, F. R.
    Ramalingam, S. S.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S551 - S552
  • [28] Second-line Chemotherapy for Patients with Small Cell Lung Cancer and Interstitial Lung Disease
    Fujimoto, Daichi
    Shimizu, Ryoko
    Kato, Ryoji
    Sato, Yuki
    Kogo, Mariko
    Ito, Jiro
    Teraoka, Shunsuke
    Otoshi, Takehiro
    Nagata, Kazuma
    Nakagawa, Atsushi
    Otsuka, Kojiro
    Katakami, Nobuyuki
    Tomii, Keisuke
    ANTICANCER RESEARCH, 2015, 35 (11) : 6261 - 6266
  • [29] The role of topotecan in treating small cell lung cancer: second-line treatment
    von Pawel, J
    LUNG CANCER, 2003, 41 : S3 - S8
  • [30] Second-line treatment of advanced non-small cell lung cancer
    Gridelli, Cesare
    Ardizzoni, Andrea
    Ciardiello, Fortunato
    Hanna, Nasser
    Heymach, John V.
    Perrone, Francesco
    Rosell, Rafael
    Shepherd, Frances A.
    Thatcher, Nick
    Vansteenkiste, Johan
    De Petris, Luigi
    Di Maio, Massimo
    De Marinis, Filippo
    JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (04) : 430 - 440
12345